- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02329782
Supporting Treatment Adherence Readiness Through Training (START) (START)
Controlled Evaluation of the Adherence Readiness Program for ART Adherence
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
California
-
Long Beach, California, Соединенные Штаты
- CaRe Clinic
-
Los Angeles, California, Соединенные Штаты
- T.H.E. Clinic
-
Los Angeles, California, Соединенные Штаты
- UCLA CARE Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
The patient's provider views the patient as medically appropriate to begin (ART naïve) or restart ART (has been off ART for at least 2 months), and either
- plans to start the patient on ART
- would like to start the patient on ART but the provider or patient is uncertain about the patient's readiness to adhere well.
Patients who are currently on ART are also eligible if they meet the following criteria, which are specific only to this type of patient:
i) the patient has 2 or more HIV viral load tests in the past year > 1000 copies/ml ii) the patient has had no HIV viral load tests that were undetectable in the past year iii) the patient has a genotype in the past year that does not show resistance as a reason for virologic failure (detectable viral load) iv) primary care provider views the patient as a good candidate for the study, with the understanding that the patient will interrupt ART if assigned to the intervention.
Criteria i to iii are intended to define a subgroup of nonadherent patients who are taking very little of their ART medications, as evidenced by the combination of consistently high viral load and no drug resistance. If the patient was taking at least a moderate level of drug and still had consistently high viral load, than they would have evidence of drug resistance. Providers are generally comfortable with this type of patient stopping their medication in order to facilitate the pre-treatment, adherence readiness assessment and training phase of the intervention prior to restarting the patient on treatment.
- The patient's health status is stable. There is no current acute OI or medical condition that calls for immediate ART, as determined by the patient's provider.
- Most recent HIV viral load is detectable.
- If CD4 < 200, the patient is on or will be prescribed prophylactic medication
- Patient is 18 or older.
- Patient is able and willing to give informed consent.
- English speaking.
Exclusion Criteria:
1. Patient just tested HIV+ and their provider suspects the patient may be acutely or recently infected (within past 6 months).
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: ARP intervention
Adherence counseling intervention
|
The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
|
|
Без вмешательства: usual care
no intervention, standard care practices regarding adherence support
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
HIV virologic suppression
Временное ограничение: Month 24
|
undetectable HIV viral load at time of assessment
|
Month 24
|
|
log change in HIV viral load (log change in HIV RNA levels)
Временное ограничение: Month 24
|
log change in HIV RNA levels from baseline to Month 24.
|
Month 24
|
|
optimal dose-taking adherence (whether at least 85% of prescribed doses were taken)
Временное ограничение: Month 24
|
binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 24
|
Month 24
|
|
percent dose-taking adherence
Временное ограничение: Month 24
|
percent of prescribed doses taken between baseline and Month 24
|
Month 24
|
|
HIV virologic suppression
Временное ограничение: Month 6
|
undetectable HIV viral load at time of assessment
|
Month 6
|
|
log change in HIV viral load (log change in HIV RNA levels)
Временное ограничение: Month 6
|
log change in HIV RNA levels from baseline to Month 6
|
Month 6
|
|
optimal dose-taking adherence (whether at least 85% of prescribed doses were taken)
Временное ограничение: month 6
|
binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 6
|
month 6
|
|
percent dose-taking adherence
Временное ограничение: month 6
|
percent of prescribed doses taken between baseline and Month 6
|
month 6
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
dose-timing adherence
Временное ограничение: Month 24
|
percent of prescribed doses taken within correct time-window between baseline and Month 24
|
Month 24
|
|
dose-timing adherence
Временное ограничение: Month 6
|
percent of prescribed doses taken within correct time-window between baseline and Month 6
|
Month 6
|
|
optimal dose-timing adherence
Временное ограничение: Month 24
|
binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 24
|
Month 24
|
|
optimal dose-timing adherence
Временное ограничение: Month 6
|
binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 6
|
Month 6
|
|
change in CD4 count
Временное ограничение: Month 24
|
change in CD4 count from baseline to Month 24
|
Month 24
|
|
change in CD4 count
Временное ограничение: Month 6
|
change in CD4 count from baseline to Month 6
|
Month 6
|
|
clinic attendance (number of missed clinic appointments)
Временное ограничение: Month 24
|
number of missed clinic appointments between baseline and Month 24
|
Month 24
|
|
clinic attendance (number of missed clinic appointments)
Временное ограничение: Month 6
|
number of missed clinic appointments between baseline and Month 6
|
Month 6
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Glenn Wagner, PhD, RAND
Публикации и полезные ссылки
Общие публикации
- Wagner GJ, Seelam R, Hoffman R, Ghosh-Dastidar B. Mediators and moderators of ART adherence effects of supporting treatment adherence readiness through training (START): evidence that START helps vulnerable clients achieve better adherence. AIDS Care. 2022 Oct;34(10):1249-1256. doi: 10.1080/09540121.2021.2006133. Epub 2021 Nov 21.
- Wagner GJ, Hoffman R, Linnemayr S, Schneider S, Ramirez D, Gordon K, Seelam R, Ghosh-Dastidar B. START (Supporting Treatment Adherence Readiness through Training) Improves Both HIV Antiretroviral Adherence and Viral Reduction, and is Cost Effective: Results of a Multi-site Randomized Controlled Trial. AIDS Behav. 2021 Oct;25(10):3159-3171. doi: 10.1007/s10461-021-03188-x. Epub 2021 Apr 2.
- Wagner GJ, Linnemayr S, Ghosh-Dastidar B, Currier JS, Hoffman R, Schneider S. Supporting Treatment Adherence Readiness through Training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial. Trials. 2016 Mar 24;17:162. doi: 10.1186/s13063-016-1287-3.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- MH104086
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .